



## OA RENEWS CONTRACT FOR ETHYOL<sup>®</sup> WITH MEDIMMUNE ONCOLOGY, INC.

Oncology Associates is pleased to announce that it has renewed its contract for Ethyol<sup>®</sup> with MedImmune Oncology, Inc.

Ethyol<sup>®</sup> (amifostine) is a selective cytoprotective agent used to reduce toxicities associated with certain cancer chemotherapy and radiotherapy. Specifically, Ethyol<sup>®</sup> is an intravenous organic thiophosphate cytoprotective agent indicated for the reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer (NSCLC). Ethyol<sup>®</sup> is also indicated to reduce the incidence of moderate to severe xerostomia (chronic dry mouth) in patients undergoing post-

operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.

John Christopher, President of Oncology Associates commented, "We are proud to have a partnership with MedImmune, as they are continuously making medical breakthroughs in the treatment of side effects associated with anti-cancer therapy."

For more information on MedImmune Oncology and Ethyol<sup>®</sup>, visit their web site at [www.medimmune.com](http://www.medimmune.com). If your practice is interested in joining the MedImmune Oncology contract for Ethyol<sup>®</sup>, contact Oncology Associates at 888-732-7352.

PRODUCT	STRENGTH/SIZE	SELLING UNIT	NDC #	% DISCOUNT OFF WAC
Ethyol <sup>®</sup>	500mg/10mL vial	1 box of 3 vials	58178-017-03	2%
Ethyol <sup>®</sup>	500mg/10mL vial	1 box of 3 vials	17314-7253-3	2%



## NEW CONTRACT AVAILABLE FOR BEDFORD LABS' PACLITAXEL<sup>®</sup>

Oncology Associates is pleased to announce Bedford Laboratories' Paclitaxel<sup>®</sup> is now available to OA Members, effective January 21, 2003.

Paclitaxel<sup>®</sup> is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. Paclitaxel<sup>®</sup> is also indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have

included an anthracycline unless clinically contraindicated.

"We are pleased to have a generic alternative of such an important drug under contract again," states Brent Evans, Executive Vice President and General Manager of Oncology Associates. "We look forward to continuously growing our partnership with Bedford Labs and expanding the list of chemotherapy agents offered to our members."

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products.

NDC #	PRODUCT NAME	SIZE
55390-0114-50	Paclitaxel <sup>®</sup>	300 mg
55390-0114-20	Paclitaxel <sup>®</sup>	100 mg
55390-0114-05	Paclitaxel <sup>®</sup>	30 mg